Two UCSF pediatric hematologist-oncologists discuss COVID risks for pediatric patients with sickle cell and other blood diseases or cancer. Guidance includes which children need hospitalization, when to give preventive therapies for coagulopathies, and when to delay – or not delay – regularly scheduled treatments.
Published
July 16, 2020
Created by
Related Presenters
Professor of Clinical Pediatrics, UCSF
Dr. Robert E. Goldsby is a pediatric cancer specialist at UCSF Benioff Children's Hospitals. He directs the UCSF Survivors of Childhood Cancer Program, which provides care and long-term follow-up for patients who had cancer in childhood. ...
Associate Professor of Pediatrics, UCSF
Pediatric Hematologist-Oncologist
Dr. Robert Raphael is a pediatric hematologist-oncologist who cares for young patients with any form of childhood cancer or blood disease. His primary focus in patient care is treating cancer, with particular interests in lymphomas and ...
